Aardvark Therapeutics, Inc. Logo

Aardvark Therapeutics, Inc.

Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.

AARD | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
4370 LA JOLLA VILLAGE DRIVE, 92122 SAN DIEGO

Description

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel, small-molecule therapeutics. The company focuses on activating innate homeostatic pathways to address metabolic diseases and conditions associated with hunger. Its lead product candidate, ARD-101, is an oral investigational drug designed for the treatment of hyperphagia, particularly in rare genetic diseases. ARD-101 functions primarily within the digestive tract by activating bitter taste receptors (TAS2Rs), which triggers the local release of satiety hormones. These hormones then send signals to the brain to suppress hunger. The company aims to become a leader in treating hunger, with potential applications for obesity and related conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aardvark Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aardvark Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aardvark Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Develops drugs for intractable diseases by regulating oxidative stress and CAFs.
South Korea
293780
Aptamer Sciences Inc Logo
Clinical-stage company developing aptamer-based therapeutics for oncology.
South Korea
291650
Aptorum Group Ltd Logo
Clinical-stage biopharma developing therapeutics for oncology and infectious diseases.
United States of America
APM
Aquestive Therapeutics, Inc. Logo
Pharmaceutical company developing oral film medicines for CNS and allergic reactions.
United States of America
AQST
Arbutus Biopharma Corp Logo
Clinical-stage biopharma company developing a functional cure for chronic Hepatitis B.
United States of America
ABUS
Arcellx, Inc. Logo
A clinical-stage biotech company developing immunotherapies for cancer and autoimmune diseases.
United States of America
ACLX
Arctic Bioscience Logo
Develops pharmaceutical and nutraceutical products from marine membrane lipids.
Norway
ABS
ArcticZymes Technologies Logo
Develops and manufactures novel recombinant enzymes from Arctic marine organisms.
Norway
AZT
Arcturus Therapeutics Holdings Inc. Logo
A commercial-stage mRNA medicines company focused on rare and infectious diseases.
United States of America
ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharmaceutical company developing combination therapies for cancer.
United States of America
RCUS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.